William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on July 28.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matt Phipps’s rating is based on several promising developments within Upstream Bio, Inc. The company has recently completed enrollment in the Phase II VALIANT clinical trial for asthma, with top-line data expected in the first quarter of 2026. This trial is significant as it evaluates different dosing regimens of verekitug, which could potentially offer new treatment options for asthma patients.
Additionally, Upstream Bio has initiated the Phase II VENTURE clinical trial for COPD, further expanding its research into respiratory conditions. The upcoming release of top-line results from the Phase II VIBRANT clinical trial for chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 is another catalyst. The anticipated improvements in nasal polyp and congestion scores could demonstrate verekitug’s efficacy, supporting its potential as a viable treatment option. These factors collectively contribute to the positive outlook and Buy rating from Matt Phipps.
According to TipRanks, Phipps is an analyst with an average return of -4.8% and a 39.93% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Upstream Bio, Inc., Amgen, and Incyte.
In another report released on July 28, J.P. Morgan also maintained a Buy rating on the stock with a $35.00 price target.